Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
Authors
Keywords
Dacarbazine, GNAQ, GNA11, Metastatic uveal melanoma, Phase III, Selumetinib
Journal
BMC CANCER
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-06-10
DOI
10.1186/s12885-015-1470-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
- (2014) Fa-Xing Yu et al. CANCER CELL
- Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry
- (2014) Xiaodong Feng et al. CANCER CELL
- Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
- (2014) Richard D. Carvajal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma
- (2014) Marliese Alexander et al. MEDICAL JOURNAL OF AUSTRALIA
- Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)
- (2013) Sander Kelderman et al. ACTA ONCOLOGICA
- Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
- (2013) M. Maio et al. ANNALS OF ONCOLOGY
- Clinical activity of ipilimumab for metastatic uveal melanoma
- (2013) Jason J. Luke et al. CANCER
- Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
- (2013) Caroline Robert et al. LANCET ONCOLOGY
- Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death
- (2013) G. Ambrosini et al. MOLECULAR CANCER THERAPEUTICS
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) R. Dummer et al. ANNALS OF ONCOLOGY
- The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
- (2012) S V Holt et al. BRITISH JOURNAL OF CANCER
- Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance
- (2012) G. Ambrosini et al. CLINICAL CANCER RESEARCH
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Ipilimumab activity in advanced uveal melanoma
- (2012) Muhammad Adnan Khattak et al. MELANOMA RESEARCH
- Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
- (2011) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Mutations inGNA11in Uveal Melanoma
- (2010) Catherine D. Van Raamsdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of Treatments for Metastatic Uveal Melanoma
- (2009) James J. Augsburger et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma
- (2009) J Bauer et al. BRITISH JOURNAL OF CANCER
- A recycling framework for the construction of Bonferroni-based multiple tests
- (2009) C.-F. Burman et al. STATISTICS IN MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now